Dueling Records: Are Statements in Your 510(k) Putting Your Patents at Risk?
28 October 2015
Attorneys Jolene Fernandes, James Ewing, Lisamarie Collins, Jacki Lin and Linda Wu contributed an article to Bloomberg BNA’s Medical Devices Law & Industry Report, “Dueling Records: Are Statements in Your 510(k) Putting Your Patents at Risk?,” on October 28, 2015. The article laboratory developed test (LDT) providers and new U.S. Food and Drug Administration (FDA) oversight that requires LDTs providers to consider if their LDTs constitute moderate-risk or high-risk devices subject to FDA oversight. The article reviews emerging areas of regulation for LDT providers; 510(k) statements and real world consequences to patent assets; and practical solutions for mitigating risk.
Author(s)
Related Insights
15 November 2024
Events
Chevron’s Demise and its Impact on Health Care
Foley partner Judy Waltz, co-chair of Foley’s Health Care Practice Group, is speaking in the California Society for Healthcare Attorneys’ 2024 Fall Seminar in a panel titled “Chevron’s Demise and its Impact on Health Care” on November 15.
12 November 2024
Events
2024 NAM Manufacturing Legal Summit
The National Association of Manufacturers will be hosting its third annual Manufacturing Legal Summit on November 12-13 in Washington D.C at the Willard InterContinental. The conference is for manufacturing lawyers addressing the latest pressing challenges across the legal regulatory landscape.
19 September 2024
Viewpoints
SEC’s Focus on Whistleblower Protection Practices Continues
On September 9, 2024, the U.S. Securities and Exchange Commission announced that it settled charges against seven public companies for alleged violations of Securities Exchange Act Rule 21F-17.